Early screening method and kit for non-alcoholic fatty liver disease susceptibility genes
A fatty liver disease and susceptibility gene technology, applied in the field of early screening methods and kits for non-alcoholic fatty liver disease susceptibility genes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0093] Feasibility analysis of SNP site screening of human non-alcoholic fatty liver disease susceptibility-related genes
[0094] By searching NCBI home and abroad genome-wide association study (genome-wide association study, GWAS) in large-scale pathological control group clinical research of the relevant sites of non-alcoholic fatty liver disease, the inventors screened and Evaluation, selected 10 single nucleotide polymorphism sites that are significantly associated with the risk of non-alcoholic fatty liver disease in the Chinese population, and are independent of each other, there is no linkage disequilibrium, so the site selection of the present invention is representative , independence and cumulative risk value, which can be used to assess the risk of individuals suffering from non-alcoholic fatty liver disease.
[0095] The screened SNP sites are as follows:
[0096]rs738409, rs58542926, rs780094, rs641738, rs72613567, rs3480, rs7674434, rs12152703, rs5764455, rs600...
Embodiment 2
[0097] Embodiment 2 system verification
[0098] System validation includes accuracy, specificity, sensitivity, precision, and comparison among personnel.
[0099] Accuracy verification scheme: 20 cases were detected at each site, compared with Sanger sequencing, the expected target was 95%.
[0100] Specificity Validation Protocol: Included in Accuracy, expected target 95%.
[0101] Sensitive verification scheme: using human genomic DNA positive samples as templates, the DNA contents of calibration samples were 1ng / μL, 5ng / μL, 10ng / μL, 50ng / μL, and 100ng / μL for sensitivity inspection.
[0102] The precision verification plan (including intra-batch, inter-batch, and personnel comparisons, not involving inter-instrument comparisons) has an expected target of 95%.
[0103] Intra-assay precision: The same batch of each sample was repeated 3 times to compare the intra-assay precision.
[0104] Inter-batch precision: The same operator tests the same sample in multiple batches to...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com